Sachin Jain
Stock Analyst at Bank of America Securities
(3.30)
# 2,424
Out of 4,476 analysts
261
Total ratings
57%
Success rate
3.2%
Average return
Main Sectors:
Stocks Rated by Sachin Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,500p | $14,456.00 | +14.14% | 79 | Jul 2, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €92.00 | $75.81 | +21.36% | 21 | Jul 2, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 140.00 | $127.92 | +9.44% | 26 | Jul 1, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,350p | $2,015.00 | +16.63% | 14 | Jun 30, 2026 | |
| NVS Novartis AG | Maintained: Buy | $173 | $159.90 | +8.11% | 3 | Jun 11, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 340.00 → kr 350.00 | $326.48 | +7.20% | 27 | Feb 5, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €30.00 → €35.00 | $53.36 | -34.41% | 9 | Dec 2, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 1,950 → kr 2,250 | $1,861.29 | +20.88% | 23 | Nov 25, 2025 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €10.60 | $9.02 | +17.54% | 1 | Nov 25, 2025 | |
| GSK GSK plc | Reiterated: Sell | $48 → $22 | $53.66 | -58.19% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $139 → $57 | $50.43 | +13.28% | 37 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | CHF 275.00 → CHF 340.00 | $340.60 | n/a | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €110.00 → €205.00 | $145.65 | n/a | 3 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $49 | $28.52 | n/a | 4 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $24 | $30.33 | n/a | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $195 | $79.76 | n/a | 1 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $24.32 | n/a | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $137.35 | n/a | 1 | May 2, 2016 |
AstraZeneca PLC
Jul 2, 2026
Reiterated: Buy
Price Target: 16,500p
Current: $14,456.00
Upside: +14.14%
Sanofi
Jul 2, 2026
Reiterated: Hold
Price Target: €92.00
Current: $75.81
Upside: +21.36%
Novartis AG
Jul 1, 2026
Reiterated: Buy
Price Target: CHF 140.00
Current: $127.92
Upside: +9.44%
GSK plc
Jun 30, 2026
Reiterated: Hold
Price Target: 2,350p
Current: $2,015.00
Upside: +16.63%
Novartis AG
Jun 11, 2026
Maintained: Buy
Price Target: $173
Current: $159.90
Upside: +8.11%
Novo Nordisk A/S
Feb 5, 2026
Maintained: Hold
Price Target: kr 340.00 → kr 350.00
Current: $326.48
Upside: +7.20%
Bayer Aktiengesellschaft
Dec 2, 2025
Maintained: Buy
Price Target: €30.00 → €35.00
Current: $53.36
Upside: -34.41%
Genmab A/S
Nov 25, 2025
Maintained: Buy
Price Target: kr 1,950 → kr 2,250
Current: $1,861.29
Upside: +20.88%
Grifols, S.A.
Nov 25, 2025
Maintained: Buy
Price Target: €10.60
Current: $9.02
Upside: +17.54%
GSK plc
Oct 29, 2025
Reiterated: Sell
Price Target: $48 → $22
Current: $53.66
Upside: -58.19%
Oct 9, 2025
Maintained: Hold
Price Target: $139 → $57
Current: $50.43
Upside: +13.28%
Sep 13, 2024
Upgraded: Buy
Price Target: CHF 275.00 → CHF 340.00
Current: $340.60
Upside: n/a
Jun 12, 2023
Maintained: Buy
Price Target: €110.00 → €205.00
Current: $145.65
Upside: n/a
May 11, 2023
Reiterated: Buy
Price Target: $48 → $49
Current: $28.52
Upside: n/a
Feb 2, 2023
Maintained: Hold
Price Target: $24
Current: $30.33
Upside: n/a
Jan 17, 2023
Maintained: Hold
Price Target: $195
Current: $79.76
Upside: n/a
Nov 1, 2022
Maintained: Buy
Price Target: $60
Current: $24.32
Upside: n/a
May 2, 2016
Maintained: Buy
Price Target: n/a
Current: $137.35
Upside: n/a